Tirzepatide Outperforms Semaglutide by 47% in Weight Loss
By Editor_wr On May 12, 2025
A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine.
For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2
In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm).
'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.'
Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ?10% weight loss 81.6% 60.5% Achieved ?15% weight loss 64.6% 40.1% Achieved ?20% weight loss 48.4% 27.3% Achieved ?25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm
'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.'
The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. Tirzepatide Outperforms Semaglutide by 47% in Weight Loss
Comments are closed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
12-05-2025
- Web Release
Tirzepatide Outperforms Semaglutide by 47% in Weight Loss
By Editor_wr On May 12, 2025 A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2 In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ?10% weight loss 81.6% 60.5% Achieved ?15% weight loss 64.6% 40.1% Achieved ?20% weight loss 48.4% 27.3% Achieved ?25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm 'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. Tirzepatide Outperforms Semaglutide by 47% in Weight Loss Comments are closed.
Filipino Times
26-04-2025
- Filipino Times
Hiding or spreading illness now illegal in Dubai, new law says
Dubai has issued a new law that sets strict rules for sick people and travellers entering the city. According to Law No. (5) of 2025, released by the Ruler of Dubai, and Vice President and Prime Minister of the UAE, His Highness Sheikh Mohammed bin Rashid Al Maktoum, this initiative is to stop the spread of diseases and protect the health of everyone in the emirate. Anyone infected or suspected of having a contagious disease is now required to avoid contact with others and cannot travel unless approved by the Dubai Health Authority (DHA). The law clearly states that it is illegal to hide or spread infections, whether done on purpose or not. Travellers arriving in Dubai must follow health checks and provide medical information when asked by authorities. They must also follow safety rules such as wearing masks and keeping a distance if needed. The law also covers other safety areas, including food handling, consumer product standards, pest control, and tobacco regulation. Housing standards in labour accommodations are also part of the law's focus. Both the public and private sectors are required to help enforce the new law. This means full cooperation with authorities, including sharing data and reports related to health and safety. The law aims to keep Dubai safe and ready for any health challenges. It will take effect 90 days after being published in the Official Gazette.
Gulf News
25-04-2025
- Gulf News
Dubai's new Public Health Law: What travellers need to know
Dubai: As part of a new law aimed at enhancing public health in Dubai, travellers entering the emirate must now follow specific health protocols to prevent the spread of communicable diseases. The new law outlines a wide-ranging framework to improve community health, reduce disease transmission, and align public health practices with international standards. It introduces strict obligations for travellers, individuals, and healthcare providers, while clarifying the roles of government entities in safeguarding health and the environment. In a major step to strengthen public health protection, the Government of Dubai has enacted Law No. (5) of 2025 on Public Health, issued on Wednesday by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai. The new law lays out detailed responsibilities for individuals and authorities, with a particular emphasis on disease prevention, public safety, and international health compliance. Individuals infected with or suspected of having a communicable disease are required to avoid contact that could spread the illness. They must refrain from travelling or moving, except to healthcare facilities, without the approval of the Dubai Health Authority. The law also prohibits concealing infections or spreading them, whether intentionally or unintentionally, and mandates individuals to comply with measures to prevent the spread of disease, following guidelines issued by relevant authorities and healthcare providers. These requirements are part of broader efforts to control disease transmission and ensure early detection and response. What are the rules for travellers? All travellers entering Dubai are required to: Follow official health protocols set by relevant authorities Provide accurate health information upon arrival at Dubai's entry points Report any suspected or confirmed communicable diseases to the authorities Observe hygiene practices, such as wearing face masks and maintaining physical distancing, in accordance with approved guidelines in case of any illness. Individual Responsibilities Anyone infected with, or suspected of carrying, a communicable disease must: Avoid contact with others to prevent transmission Refrain from travel or movement, except to healthcare facilities and only with the Dubai Health Authority's approval Not conceal infections or knowingly spread disease Comply with instructions from health authorities and healthcare providers. Broader framework of the law The law provides a comprehensive structure for maintaining public health across the emirate. It focuses on: Preventive measures against health risks Coordination among government entities, including the Dubai Health Authority, Dubai Municipality, and the Dubai Environment and Climate Change Authority Public education and awareness, emphasising shared responsibility for health and safety When does the law take effect?
